2026-04-17T06:55:29Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/94882024-12-13T10:05:20Zcom_2072_378071com_2072_378040col_2072_378097

Dasatinib-induced chylothorax: a clinical laboratory’s perspective García Martínez, Rafael Sanz Gea, Clara Martin Riera, Victor Guerra-Ruiz, Armando Paciucci Barzanti, Rosanna Ferrer Costa, Roser Ramírez Serra, Clara Institut Català de la Salut [Martínez RJG] Clinical Analysis Department, Marqués de Valdecilla University Hospital, Santander, Spain. Evidence-Based Laboratory Medicine Commission, Spanish Society of Laboratory Medicine (SEQCML), Barcelona, Spain. [Gea CS, Martin-Riera V, Ruiz ARG, Barzanti RP, Ferrer-Costa R, Ramirez-Serra C] Grup de Recerca de Bioquímica Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Proteïnes quinases - Inhibidors - Efectes secundaris Embassament pleural CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors Other subheadings::Other subheadings::Other subheadings::/adverse effects DISEASES::Respiratory Tract Diseases::Pleural Diseases::Chylothorax Other subheadings::Other subheadings::Other subheadings::/chemically induced COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos ENFERMEDADES::enfermedades respiratorias::enfermedades pleurales::quilotórax Otros calificadores::Otros calificadores::Otros calificadores::/inducido químicamente Dasatinib; Pleural effusion chylothorax Dasatinib; Derrame pleural quilotórax Dasatinib; Vessament pleural quilotòrax Dasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a secondary effect of dasatinib occurring especially in long-term treated patients, although its pathophysiology is not yet fully understood. Laboratory analysis of the pleural effusion is crucial for chylothorax diagnosis. We report a case of a 53-year-old male patient presenting a chylothorax after 14 years of dasatinib therapy where the clinical laboratory was key in the diagnosis. 2023-05-10T06:47:20Z 2023-05-10T06:47:20Z 2023-04-18 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion García Martínez RJ, Sanz Gea C, Martin-Riera V, Raúl A, Ruiz G, Paciucci Barzanti R, et al. Dasatinib-Induced Chylothorax: A Clinical Laboratory’s Perspective. EJIFCC. 2023 Apr 18;34(1):76. 1650-3414 https://hdl.handle.net/11351/9488 37124659 http://hdl.handle.net/11351/9488 eng EJIFCC;34(1) https://cms.ifcc.org/wp-content/uploads/2023/04/eJIFCC2023Vol34No1pp076-080.pdf Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess application/pdf International Federation of Clinical Chemistry and Laboratory Medicine Scientia